CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
SUBLICENSE REVENUE	$ 2,000	$ 0
OPERATING EXPENSES:
Sublicense Transaction Costs	254	0
General and administrative	554	641
Research and development	1,373	1,039
Total operating expenses	2,181	1,680
Income (loss) after operating expenses	(181)	(1,680)
Interest and other income (expense), net	(251)	(111)
Income (loss) from operations before taxes	(432)	(1,791)
Income tax benefit	52	36
NET INCOME (LOSS)	(380)	(1,755)
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ (380)	$ (1,755)
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ (0.01)	$ (0.04)
Basic and diluted shares outstanding	54,385	47,173